273 related articles for article (PubMed ID: 28646172)
1. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
2. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
3. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
[TBL] [Abstract][Full Text] [Related]
7. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
10. Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells.
Momeny M; Yousefi H; Eyvani H; Moghaddaskho F; Salehi A; Esmaeili F; Alishahi Z; Barghi F; Vaezijoze S; Shamsaiegahkani S; Zarrinrad G; Sankanian G; Sabourinejad Z; Hamzehlou S; Bashash D; Aboutorabi ES; Ghaffari P; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Int J Biochem Cell Biol; 2018 Jun; 99():1-9. PubMed ID: 29567488
[TBL] [Abstract][Full Text] [Related]
11. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
[TBL] [Abstract][Full Text] [Related]
13. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
[TBL] [Abstract][Full Text] [Related]
14. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
15. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
16. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
17. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells.
Hamzehlou S; Momeny M; Zandi Z; Kashani B; Yousefi H; Dehpour AR; Tavakkoly-Bazzaz J; Ghaffari SH
Eur J Pharmacol; 2019 Nov; 863():172705. PubMed ID: 31574259
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
